Covalon to Showcase AquaGuard® and IV Clear™ Products to Over 9,000 Nurses at Prestigious ANCC Magnet Conference
October 24, 2018
MISSISSAUGA, Ontario–(BUSINESS WIRE)–#ancc–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV:COV)
(OTCQX:CVALF), an advanced medical technologies company, today announces
that it will be showcasing newly-acquired moisture barrier line AquaGuard®
as part of its portfolio of infection prevention products at the 2018
American Nurses Credentialing Center National Magnet Conference (the
“Magnet Conference”). The Magnet Conference will take place at the
Colorado Convention Centre in Denver, Colorado, from October 24th
to 26th 2018, and will be Covalon’s first exhibition of
AquaGuard and IV Clear™ together as part of Covalon’s product portfolio.
The Magnet Conference is a great opportunity for Covalon’s new and
highly talented United States sales team to strengthen its already
strong relationships with clinicians and hospital staff that make
clinical use and purchasing decisions on Covalon’s product portfolio –
shower protection, vascular access dressings, surgical site management
products, and advanced wound care dressings.
“The Magnet Conference is a showcase for the best nursing practices, and
we are excited to present both IV Clear and AquaGuard to over 9,000
nursing professionals during the show,” said Brian Pedlar, Chief
Executive Officer of Covalon. “Now that Covalon has a United States
sales force and customer base of over 1,500 hospitals and clinics, the
opportunity to introduce IV Clear and Covalon’s other world-class
infection prevention products mean that many of the nurses at the Magnet
Conference will have a hands-on opportunity to see why clinicians and
patients love both IV Clear and AquaGuard. The ability for Covalon to
directly sell its strong portfolio of infection management products such
as IV Clear, MediClear Pre-Op, SurgiClear, and AquaGuard into an
established hospital base in the United States is truly transformative
to Covalon.”
On October 1st 2018, Covalon announced that it had closed the
acquisition of AquaGuard, the Seattle, Washington-based division of
medical technologies company Cenorin, LLC. AquaGuard’s specialized
products provide patients with crucial moisture protection for wound,
surgical, and vascular access sites throughout the body while showering,
which is an important step to protect patients from infections.
The Magnet Conference runs from October 24-26 2018, and Covalon will be
exhibiting in booth #764 during all exhibit hours throughout the
conference. The Magnet Recognition Program® (“Magnet”) was developed by
the American Nurses Credentialing Center (ANCC) to recognize healthcare
organizations that provide exceptional nursing care and to uphold the
tenets of professional nursing practice. Magnet is the leading source of
successful nursing practices and strategies worldwide and expects over
9,000 nursing professionals from leading hospitals in the United States
and 20 other countries to attend this year’s conference.
About Covalon
Covalon Technologies Ltd. researches,
develops, and commercializes new healthcare technologies that help save
lives around the world. Covalon’s patented technologies, products, and
services address the advanced healthcare needs of medical device
companies, healthcare providers, and individual consumers. Covalon’s
technologies are used to prevent, detect, and manage medical conditions
in specialty areas such as infection control, vascular access, surgical
procedures, advanced wound care, and medical device coatings. To learn
more about Covalon, visit our website at www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect
the Company’s current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as “seek”, “anticipate”, “plan, “estimate”, “expect”,
“intend” and statements that an event or result “may”, “will”, “should”,
“could” or “might” occur or be achieved and other similar expressions.
These forward-looking statements involve risk and uncertainties,
including completion of integration of the AquaGuard acquisition, the
difficulty in predicting product approvals, acceptance of and demands
for new products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or achievements to
differ materially from the results discussed or implied in the
forward-looking statements. Many risks are inherent in the industry;
others are more specific to the Company. Investors should consult the
Company’s ongoing quarterly filings for additional information on risks
and uncertainties relating to these forward-looking statements.
Investors should not place undue reliance on any forward-looking
statements. The Company assumes no obligation to update or alter any
forward-looking statements whether as a result of new information,
further events or otherwise.
Contacts
Covalon Technologies Ltd.
Brian Pedlar, 905-568-8400 x 233
CEO
bpedlar@covalon.com
Toll
free: 1-877-711-6055
Web site: www.covalon.com
Twitter:
@covalon